Small font size A Larger text size A Largest text size A

Royalty Pharma Prices $2 Billion Debt Offering

BY MT Newswires | CORPORATE | 09/03/25 04:11 AM EDT

04:11 AM EDT, 09/03/2025 (MT Newswires) -- Royalty Pharma (RPRX) said late Tuesday it has priced an offering of $2 billion worth of senior unsecured notes.

The offering is comprised of $600 million of 4.450% notes due 2031, $900 million of 5.200% notes due 2035, and $500 million of 5.950% notes due 2055, the company said.

The offering is expected to close on Sept. 16.

Royalty Pharma (RPRX) said it plans to use the net proceeds for general corporate purposes.

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

More Fixed Income News

*--US Treasury Yields Mixed Early Tuesday Ahead of Retail Sales, ADP Employment Change, Atlanta Fed Q4 GDPNow BY MT Newswires |TREASURY 05:53 AM EST
Sterling drops, politics and BoE easing path in focus BY Reuters |ECONOMIC 05:19 AM EST
Greek industrial output rises 3.9% y/y in December BY Reuters |ECONOMIC 05:08 AM EST
Euro zone inflation to take hit from tariffs but rate cuts could offset, ECB economists find BY Reuters |ECONOMIC 05:05 AM EST

All Fixed Income News

In general the bond market is volatile, and fixed income securities carry interest rate risk. (As interest rates rise, bond prices usually fall, and vice versa. This effect is usually more pronounced for longer-term securities.) Fixed income securities also carry inflation risk and credit and default risks for both issuers and counterparties. Unlike individual bonds, most bond funds do not have a maturity date, so avoiding losses caused by price volatility by holding them until maturity is not possible.

Lower-quality debt securities generally offer higher yields, but also involve greater risk of default or price changes due to potential changes in the credit quality of the issuer. Any fixed income security sold or redeemed prior to maturity may be subject to loss.

Before investing, consider the funds' investment objectives, risks, charges, and expenses. Contact Fidelity for a prospectus or, if available, a summary prospectus containing this information. Read it carefully.

fir_news_article